Pharvaris N.V. Ordinary Shares
PHVSStock
$33.66+52.94%52W
Market Cap$2.81B
P/E—
Div yield—
Beta-2.50
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)30.96%
Price vs S&P 500 (4W)11.16%
VGM Score70.47
Market Capitalization$2.81B
Earnings Surprise History
Q4 25-0.82est. -0.73
Q1 26-0.68est. -0.83
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.26
4.35
4.35
4.35
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PHVSPharvaris N.V. Ordinary Shares | — | — | B | $33.66 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Pharvaris is a late-stage biopharmaceutical company developing deucrictibant, an oral bradykinin B2 receptor antagonist designed to prevent and treat hereditary angioedema (HAE) attacks. The company has demonstrated positive efficacy data in Phase 2 studies and is currently enrolling pivotal Phase 3 trials for both treatment and prevention indications.